Researchers from the University of Michigan trained the model using demographic and laboratory data obtained in previous clinical trials. The data described 401 patients with active Crohn’s who had been monitored while taking ustekinumab, an immunosuppressive drug, over the course of at least 42 weeks.
Once trained, the model was able to reliably identify how a Crohn’s patient who had been given one dose of ustekinumab would react to the treatment in the long term. The technology could therefore be used to predict those patients who may not respond well to biological monotherapy, saving them money and reducing delays in achieving remission.
More articles about AI:
Machine learning tool detects Alzheimer’s in brain tissue
Elon Musk’s neurotech startup falls short in funding round
FDA clears AI tool to flag pulmonary embolism in CT scans
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
